From Fragmentation to Fusion: Rethinking Information Access in Clinical Trials

The need to navigate a multitude of clinical trial vendor portals imposes a heavy burden on clinical development teams, highlighting the necessity for innovation to streamline processes and expedite trials.

Modern clinical trials involve gathering data from participants not only during each site visit, but also increasingly between site visits using a variety of non-invasive digital health technologies such as mobile applications and wearable devices.

The more data we collect during clinical trials, the more we can learn about human disease in order to make more informed decisions and bring novel therapeutics to market. However, the increasing number and complexity of clinical trial endpoints poses protocol adherence, patient engagement, and trial oversight challenges for clinical development teams.

For example, in many trials, generating performance reports can no longer be accomplished by simply logging into a single electronic data capture system (EDC) or clinical trial management system (CTMS). Instead, reports require visiting numerous vendor portals and software systems to gather the data needed to summarize overall trial status and obtain operational insights. This patchwork of portals and the manual effort required to extract and synthesize information from them is a source of frustration and delayed timelines.

Unfortunately, these challenges are expected to worsen as trial designs and discovery pipelines embrace AI-driven drug discovery, novel diagnostics, and personalized therapies (e.g. CAR-T). Significant innovation is needed to keep up with the new pace of discovery. Failure to innovate on our current clinical trial processes will slow and even prevent the progression of numerous therapies through clinical trials, placing financial strain on biopharma and minimizing patient impact.

As a leading AI organization serving the life sciences we have seen and experienced these challenges first hand and seen their impact on the successes and shortcomings of many clinical trials, all of which stem from fragmented patient and operational data. Our platform, Vivo, was developed to help clinical data teams gain access to the data they need when they need it. This is accomplished by unifying all clinical trial data sources to enable better trial oversight through reports and notifications and quality assure data for more reliable analyses.

If you are running or planning a clinical trial or want to glean more from past clinical trial data, let’s talk. At OmniScience, we take pride in partnering with leading life science organizations and would love to help your company tackle pressing data unification and analysis challenges through our platforms and services.

Written by:
Michael Bell
VP of Platforms
Julie Mocko
Director of Product Design
Published On:
March 22, 2024